Your browser doesn't support javascript.
Considering Personalized Interferon Beta Therapy for COVID-19.
Dorgham, Karim; Neumann, Avidan U; Decavele, Maxens; Luyt, Charles-Edouard; Yssel, Hans; Gorochov, Guy.
  • Dorgham K; Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France karim.dorgham@inserm.fr.
  • Neumann AU; Department of Environmental Medicine, Faculty of Medicine, Universitätsklinikum Augsburg, Augsburg, Germany.
  • Decavele M; Institute of Environmental Medicine (IEM), Helmholtz Center Munich, Augsburg, Germany.
  • Luyt CE; Médecine Intensive et Réanimation (Département R3S), Assistance Publique Hôpitaux de Paris (AP-HP), Sorbonne-Université, Hôpital Pitié-Salpêtrière, Paris, France.
  • Yssel H; Sorbonne Université, Inserm, UMRS-1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France.
  • Gorochov G; Service de Médecine Intensive Réanimation, Institut de Cardiologie, Assistance Publique Hôpitaux de Paris (AP-HP), Sorbonne-Université, Hôpital Pitié-Salpêtrière, Paris, France.
Antimicrob Agents Chemother ; 65(4)2021 03 18.
Article in English | MEDLINE | ID: covidwho-1075925
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: Aac.00065-21

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: Aac.00065-21